ABSC.F Stock Overview
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
AB Science S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.70 |
| 52 Week High | €4.46 |
| 52 Week Low | €0.000001 |
| Beta | 1.06 |
| 1 Month Change | 5.88% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -85.93% |
| 5 Year Change | -51.32% |
| Change since IPO | -88.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABSC.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | -3.7% |
| 1Y | n/a | 11.6% | 20.5% |
Return vs Industry: Insufficient data to determine how ABSC.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ABSC.F performed against the US Market.
Price Volatility
| ABSC.F volatility | |
|---|---|
| ABSC.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ABSC.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ABSC.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 89 | Alain Moussy | www.ab-science.com |
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications.
AB Science S.A. Fundamentals Summary
| ABSC.F fundamental statistics | |
|---|---|
| Market cap | US$109.86m |
| Earnings (TTM) | -US$18.03m |
| Revenue (TTM) | US$829.60k |
132.4x
P/S Ratio-6.1x
P/E RatioIs ABSC.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABSC.F income statement (TTM) | |
|---|---|
| Revenue | €777.00k |
| Cost of Revenue | €92.00k |
| Gross Profit | €685.00k |
| Other Expenses | €17.57m |
| Earnings | -€16.88m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 88.16% |
| Net Profit Margin | -2,173.10% |
| Debt/Equity Ratio | -97.2% |
How did ABSC.F perform over the long term?
See historical performance and comparison